Adding trastuzumab to standard chemotherapy in HER2-positive esophagogastric adenocarcinoma: a further step toward personalized medicine
- PMID: 21087674
- DOI: 10.1053/j.gastro.2010.11.011
Adding trastuzumab to standard chemotherapy in HER2-positive esophagogastric adenocarcinoma: a further step toward personalized medicine
Comment on
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous